| Literature DB >> 27887651 |
Preeti Kalia1, Neelima R Kumar2, Kusum Harjai3.
Abstract
BACKGROUND: Antibiotic resistance is an emerging public health problem. Centers for Disease Control and Prevention (CDC) has described antibiotic resistance as one of the world's most pressing health problems in 21st century. WHO rated antibiotic resistance as "one of the three greatest threats to human health". One important strategy employed to overcome this resistance is the use of combination of drugs. Many plants, natural extracts have been shown to exhibit synergistic response with standard drugs against microorganisms. The present study focused on the antibacterial potential of propolis in combination with the standard antibiotic Cefixime against the typhoid causing bacteria i.e. Salmonella.Entities:
Keywords: Antibacterial; Cefixime; Propolis; Salmonella; Synergy; Typhoid
Mesh:
Substances:
Year: 2016 PMID: 27887651 PMCID: PMC5124282 DOI: 10.1186/s12906-016-1474-5
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Percentage survival of animals
| Groups | Percentage (%) Survival of animals | ||
|---|---|---|---|
| At start of treatment | End of treatment | Follow up | |
| Normal | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| Infected | 100 ± 0 | 94.94 ± 9.62 | NS |
| OC | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| OP | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| C | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| P | 100 ± 0 | 77.53 ± 9.98 | 77.53 ± 9.98 |
| CP1 | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| CP2 | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| CP3 | 100 ± 0 | 100 ± 0 | NS |
| CP4 | 100 ± 0 | 94.94 ± 9.62 | NS |
Data is expressed as mean ± SD (n = 6), NS: No mice survived
Bacterial load in blood of mice after Salmonella enterica serovar Typhimurium infection and during the course of treatment in combination therapy
| Time | 0–4 h | 4–8 h | 8–12 h | 12–24 h | 72 h | 120 h |
|---|---|---|---|---|---|---|
| Groups | ||||||
| Infected | 4.16 ± 0.14 | 5.46 ± 0.07 | 4.57 ± 0.06 | 4.47 ± 0.1 | 5.34 ± 0.14 | 6.57 ± 0.15 |
| C | 4.25 ± 0.15 | 4.86 ± 0.19 | 3.64 ± 0.3 | 3.07 ± 0.005 | 2.57 ± 0.2# | 0#^ |
| P | 4.27 ± 0.18 | 4.34 ± 0.25 | 4.21 ± 0.31 | 4.12 ± 0.17 | 3.5 ± 0.46 | 3.36 ± 0.25#@ |
| CP1 | 4.34 ± 0.15 | 4.5 ± 0.19 | 4.1 ± 0.30 | 3.36 ± 0.005 | 3.51 ± 0.2 | 2.15 ± 0#@ |
| CP2 | 4.57 ± 0.11 | 4.34 ± 0.26 | 4.21 ± 0.18 | 4.12 ± 0.48 | 3.5 ± 0.19 | 3.12 ± 0.18#@ |
| CP3 | 4.27 ± 0.18 | 4.34 ± 0.25 | 4.21 ± 0.31 | 4.12 ± 0.17 | 3.5 ± 0.46 | 3.36 ± 0.25#@ |
| CP4 | 4.54 ± 0.06 | 5.53 ± 0.39 | 5.86 ± 0.17 | 5.47 ± 0.19 | 4.34 ± 0.06 | 4.24 ± 0.13@ |
Data is expressed as mean ± SD
# p value Infected vs C, P, CP1, CP2, CP3 and CP4
@ p-value C vs P, CP1, CP2, CP3 and CP4
^ p-value P vs C, CP1, CP2, CP3 and CP4
(*@^ p < 0.05: statistically significant), (# p < 0.001: statistically very significant)
Fig. 1Histogram showing the bacterial load in different organs of mice after Salmonella enterica serovar Typhimurium infection and treatment in combination groups. Data is expressed as mean ± SD. # p-value Infected liver vs treated liver, * p-value Infected spleen vs treated spleen. $ p-value Infected kidney vs treated kidney. @ p-value C vs P, CP1, CP2, CP3 and CP4. ^ p-value P vs C, CP1, CP2, CP3 and CP4. (@^ p < 0.05), (#*$ p < 0.001)
Results of liver, kidney function tests and levels of protein and glucose in the serum of experimental groups
| Group | ALT | AST | ALP | Bilirubin | Urea | BUN | Uric Acid | Creatinine | T. Protein | Glucose |
|---|---|---|---|---|---|---|---|---|---|---|
| Normal | 21.4 ± 0.87 | 25.97 ± 1.04 | 8.57 ± 0.73 | 0.85 ± 0.12 | 43.26 ± 0.9 | 19.89 ± 0.41 | 3.03 ± 0.2 | 0.38 ± 0.056 | 6.93 ± 0.23 | 133.33 ± 6.67 |
| Infected | 140.57 ± 1.27$ | 94.03 ± 3.5$ | 28.33 ± 1.52$ | 2.2 ± 0.17$ | 82.76 ± 5.68$ | 38.07 ± 2.6$ | 6.26 ± 0.25$ | 0.78 ± 0.02$ | 5.2 ± 0.4$ | 108.33 ± 3.85$ |
| OC | 19.76 ± 0.60 | 25.5 ± 1.44 | 8.66 ± 0.57 | 0.72 ± 0.035 | 44.5 ± 1.80 | 20.47 ± 0.82 | 4.93 ± 0.11 | 0.34 ± 0.02 | 6.95 ± 0.23 | 135.56 ± 3.85 |
| OP | 35.43 ± 4.9 | 19.66 ± 0.57 | 7.66 ± 0.5 | 0.74 ± 0.04 | 43.86 ± 1.62 | 20.49 ± 0.88 | 3 ± 0.1 | 0.3 ± 0.02 | 6.533 ± 0.23 | 135.55 ± 3.85 |
| C | 23.3 ± 2.23# | 26.44 ± 3.23# | 8.77 ± 0.36# | 0.66 ± 0.06# | 43.86 ± 1.62# | 20.49 ± 0.88# | 3 ± 0.1# | 0.34 ± 0.01# | 6.76 ± 0.05# | 135.55 ± 3.85# |
| P | 51.46 ± 3.1# | 35.43 ± 4.9# | 15.2 ± 2.85# | 0.7 ± 0.04# | 52.7 ± 2.94# | 24.23 ± 1.35# | 4.24 ± 0.41# | 0.41 ± 0.02# | 7.06 ± 0.23# | 131.1 ± 3.85# |
| CP1 | 22.33 ± 0.57#^ | 27.33 ± 3.05# | 8.72 ± 0.42# | 0.66 ± 0.06# | 44.5 ± 1.8# | 20.47 ± 0.82# | 3.03 ± 0.05# | 0.3 ± 0.01# | 6.77 ± 0.04# | 137.77 ± 3.85# |
| CP2 | 23.3 ± 2.23#^ | 33.32 ± 2.88 # | 10.33 ± 2.88# | 0.66 ± 0.02*@ | 43.96 ± 1.76#^ | 20.22 ± 0.81#^ | 3.16 ± 0.15#@ | 0.39 ± 0.04# | 7.06 ± 0.23# | 133.11 ± 7# |
| CP3 | 88.57 ± 3.9#@^ | 51.73 ± 2.82 #@^ | 17.86 ± 1.76#@ | 0.83 ± 0.03# | 65.3 ± 4.65#@^ | 30.03 ± 2.14#@^ | 5.2 ± 0.43@ | 0.69 ± 0.01*@^ | 5.86 ± 0.46@^ | 111.1 ± 3.85@^ |
| CP4 | 139.67 ± 0.58@^ | 93.1 ± 2.07@^ | 27.33 ± 0.57@^ | 2.1 ± 0.17@^ | 79.66 ± 0.57@^ | 36.64 ± 0.26@^ | 5.9 ± 0.17@^ | 0.71 ± 0.02@^ | 5.06 ± 0.23@^ | 108.88 ± 3.85@^ |
Data is expressed as mean ± SD. (ANOVA: Tukey test)
$ p-value Normal vs Infected, OC, OP (p < 0.001: statistically very significant)
*# p-value Infected vs C, P, CP1, CP2, CP3, CP4
@ p-value C vs P, CP1, CP2, CP3 and CP4
^ p-value P vs C, CP1, CP2, CP3 and CP4
(*@^ p < 0.05: statistically significant), ($# p < 0.001: statistically very significant)
Results of hematological indices in the blood of experimental groups
| Group | RBC | TLC/mm3 | Hb | PCV | MCV | MCH | MCHC |
|---|---|---|---|---|---|---|---|
| Normal | 8.36 ± 1.2 | 7730 ± 170.88 | 12.48 ± 0.66 | 42 ± 1 | 48.83 ± 3.85 | 13.68 ± 1.88 | 29.27 ± 0.82 |
| Infected | 4.37 ± 0.95$ | 5766.66 ± 28.86$ | 9.06 ± 0.11$ | 28 ± 1$ | 64.17 ± 0.14$ | 21.02 ± 0.75$ | 34.13 ± 3.89$ |
| OC | 6.90 ± 0.70 | 7669.33 ± 111.26 | 12.31 ± 0.15 | 41.66 ± 1.52 | 53.63 ± 5.94 | 17.72 ± 2.13 | 33.01 ± 0.50 |
| OP | 8.06 ± 0.66 | 7348.33 ± 47.52$ | 12.6 ± 0.55 | 44 ± 1.73 | 53.49 ± 3.79 | 14.82 ± 1.23 | 28.68 ± 1.35 |
| C | 7.76 ± 0.58* | 7563 ± 32.14# | 11.56 ± 0.4# | 40.33 ± 0.57# | 52.12 ± 3.84* | 15.89 ± 3.26# | 28.68 ± 1.35# |
| P | 8.06 ± 0.66* | 7348.33 ± 47.52# | 12.6 ± 0.55# | 44 ± 1.73# | 53.49 ± 3.79* | 14.82 ± 1.23# | 28.69 ± 2.3* |
| CP1 | 8 ± 0.95* | 7091.66 ± 141.8# | 12.4 ± 0.3# | 40.5 ± 2.45# | 53.84 ± 6.03* | 15.59 ± 1.58# | 30.7 ± 2.2* |
| CP2 | 7.59 ± 0.45* | 7073.33 ± 110.15#@^ | 13.5 ± 0.82# | 40.2 ± 2.1# | 53.2 ± 6.01* | 17.64 ± 2.16 | 30.93 ± 0.05* |
| CP3 | 6.46 ± 0.05 | 6903.33 ± 41.63#@^ | 11.1 ± 0.1* | 33.26 ± 2.58*@^ | 51.41 ± 3.55* | 17.16 ± 0.21 | 33.49 ± 2.76 |
| CP4 | 4.6 ± 0.69@^ | 5885 ± 186.21@^ | 10.7 ± 0.34@^ | 28.83 ± 0.57@^ | 62.9 ± 1.96 | 20.41 ± 1.28 | 33.59 ± 0.57 |
Data is expressed as mean ± SD. (ANOVA : Tukey test)
$ p-value Normal vs Infected, OC, OP (p < 0.001: statistically very significant)
*# p-value Infected vs C, P, CP1, CP2, CP3, CP4
@ p-value C vs P, CP1, CP2, CP3 and CP4
^ p-value P vs C, CP1, CP2, CP3 and CP4
(*@^ p < 0.05: statistically significant), ($# p < 0.001: statistically very significant)
Plate IHaematoxylin and eosin stained transverse sections of liver of normal (a, b, c) and Salmonella enterica serovar Typhimurium infected BALB/c mice (d, e, f)
Plate IIHaematoxylin and Eosin stained transverse sections of liver of combination therapy groups CP1 (a), CP2 (b and c), CP3 (d), CP4 (e and f)
Plate IIIHaematoxylin and eosin stained transverse sections of spleen of normal (a, b, c) and Salmonella enterica serovar Typhimurium infected BALB/c mice (d, e, f)
Plate IVHaematoxylin and Eosin stained transverse sections of spleen of combination therapy groups CP1 (a), CP2 (b), CP3 (c and d), CP4 (e and f)
Plate VHaematoxylin and eosin stained transverse sections of kidney of normal (a, b, c) and Salmonella enterica serovar Typhimurium infected BALB/c mice (d, e, f)
Plate VIHaematoxylin and Eosin stained transverse sections of kidney of combination therapy groups CP1 (a and b), CP2 (c and d), CP3 (e), CP4 (f)